» Articles » PMID: 33467425

Comprehensive Overview of Gene Rearrangements in Childhood T-Cell Acute Lymphoblastic Leukaemia

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 20
PMID 33467425
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Acute lymphoblastic leukaemia (ALL) is a relevant form of childhood neoplasm, as it accounts for over 80% of all leukaemia cases. T-cell ALL constitutes a genetically heterogeneous cancer derived from T-lymphoid progenitors. The diagnosis of T-ALL is based on morphologic, immunophenotypic, cytogenetic, and molecular features, thus the results are used for patient stratification. Due to the expression of surface and intracellular antigens, several subtypes of T-ALL can be distinguished. Although the aetiology of T-ALL remains unclear, a wide spectrum of rearrangements and mutations affecting crucial signalling pathways has been described so far. Due to intensive chemotherapy regimens and supportive care, overall cure rates of more than 80% in paediatric T-ALL patients have been accomplished. However, improved knowledge of the mechanisms of relapse, drug resistance, and determination of risk factors are crucial for patients in the high-risk group. Even though some residual disease studies have allowed the optimization of therapy, the identification of novel diagnostic and prognostic markers is required to individualize therapy. The following review summarizes our current knowledge about genetic abnormalities in paediatric patients with T-ALL. As molecular biology techniques provide insights into the biology of cancer, our study focuses on new potential therapeutic targets and predictive factors which may improve the outcome of young patients with T-ALL.

Citing Articles

Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.

Ramirez Maldonado V, Navas Acosta J, Maldonado Marcos I, Villaverde Ramiro A, Hernandez-Sanchez A, Hernandez Rivas J Cancers (Basel). 2024; 16(23).

PMID: 39682152 PMC: 11639785. DOI: 10.3390/cancers16233965.


Cytogenomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals TCR rearrangements as predictive factors for exceptional prognosis.

Lizcova L, Prihodova E, Pavlistova L, Svobodova K, Mejstrikova E, Hrusak O Mol Cytogenet. 2024; 17(1):14.

PMID: 38783324 PMC: 11118568. DOI: 10.1186/s13039-024-00682-4.


Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL.

Vieler L, Nilius-Eliliwi V, Schroers R, Vangala D, Nguyen H, Gerding W Genes (Basel). 2023; 14(3).

PMID: 36980958 PMC: 10048194. DOI: 10.3390/genes14030686.


The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Lato M, Przysucha A, Grosman S, Zawitkowska J, Lejman M Int J Mol Sci. 2021; 22(9).

PMID: 33925883 PMC: 8123476. DOI: 10.3390/ijms22094502.

References
1.
Homig-Holzel C, Savola S . Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol. 2012; 21(4):189-206. DOI: 10.1097/PDM.0b013e3182595516. View

2.
Zhang Y, Gao Y, Zhang H, Zhang J, He F, Hnizda A . mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018; 131(20):2256-2261. PMC: 5958655. DOI: 10.1182/blood-2017-11-817510. View

3.
Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R . Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004; 82(1):341-58. DOI: 10.1093/toxsci/kfh254. View

4.
Kang H, Sharma N, Nickl C, Devidas M, Loh M, Hunger S . Dysregulated transcriptional networks in and -rearranged T-ALL. Biomark Res. 2018; 6:27. PMC: 6107954. DOI: 10.1186/s40364-018-0141-z. View

5.
Liu R, Guo J, Liu T, Guo C, Fan X, Zhang X . Meta-analysis of the clinical characteristics and prognostic relevance of NOTCH1 and FBXW7 mutation in T-cell acute lymphoblastic leukemia. Oncotarget. 2017; 8(39):66360-66370. PMC: 5630418. DOI: 10.18632/oncotarget.18576. View